Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera) announced that its recent resubmission of the New Drug Application (NDA) for ILUVIEN® has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE